All In Biotech

Drug Trial Radar · NCT06150924

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

A Randomized, Crossover, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors, in Adults With Hypertension and Chronic Kidney Disease With Albuminuria

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Dec 14, 2023

Primary completion

Feb 27, 2025

Study completion Apr 23, 2025

Sponsor

Lead sponsor
Mineralys Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Nov 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor \[ASI\]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB). Subjects will be at least 18 years old with hypertension, and mild to severe CKD with albuminuria at the Screening Visit.

Conditions

  • Chronic Kidney Disease

Interventions

  • Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QDDrug

    Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks

  • Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QDDrug

    Period 1 - Placebo QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Lorundrostat 25mg + SGLT2i QD 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4Time frame: Baseline to Week 4

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Kidney Disease & Hypertension Centers (AKDHC) - Thunderbird Office

    Glendale, Arizona

  • Arizona Kidney Disease & Hypertension Centers (AKDHC) - Thomas Office

    Phoenix, Arizona

  • Balboa Nephrology Medical Group, Inc. (BNMG) - California Institute of Renal Research (CIRR) - Chula Vista

    Chula Vista, California

  • Balboa Nephrology Medical Group, Inc. (BNMG) - El Centro

    El Centro, California

  • Amicis Research Center - Granada Hills

    Granada Hills, California

  • Balboa Nephrology Medical Group, Inc. (Bnmg) - La Mesa

    La Mesa, California

  • Academic Medical Research Institute (AMRI) - Los Angeles

    Los Angeles, California

  • Amicis Research Center

    Northridge, California

  • Amicis Research Center - Vacaville

    Vacaville, California

  • Colorado Kidney Care (Denver Nephrology) - Denver Office

    Denver, Colorado

  • Qway Research

    Coconut Grove, Florida

  • Indago Research and Health Center

    Hialeah, Florida

  • Elixia Pines, LLC

    Hollywood, Florida

  • Elixia Central Florida, LLC

    Orlando, Florida

  • Infigo Clinical Research, Llc

    Sanford, Florida

  • Genesis Clinical Research - Tampa

    Tampa, Florida

  • Palm Beach Diabetes and Endocrine Specialists, PA (PBDES) - West Palm Beach Office

    West Palm Beach, Florida

  • American Clinical Trials Llc

    Acworth, Georgia

  • Nephrology of the Golden Isles - Brunswick

    Brunswick, Georgia

  • ClinCept, LLC

    Columbus, Georgia

  • Georgia Nephrology, Llc

    Lawrenceville, Georgia

  • Nephrology Associates of Kentuckiana, PSC (NAK)

    Louisville, Kentucky

  • Lcms Health University Medical Center New Orleans

    New Orleans, Louisiana

  • Northwest Louisiana Nephrology, Llc - Shreveport

    Shreveport, Louisiana

  • Tufts University School of Medicine (Tusm) - Tufts Medical Center (Tmc) (Tufts-New England Medical Center)

    Boston, Massachusetts

  • Elixia MKC, LLC

    Pontiac, Michigan

  • Kansas City Kidney Consultants (Arms, Dodge, Robinson, Wilber & Crouch, Inc.) - Kansas City

    Kansas City, Missouri

  • Seacoast Kidney & Hypertension Specialists - Portsmouth Office

    Portsmouth, New Hampshire

  • Suny Downstate Medical Center - Parkside Dialysis Center

    Brooklyn, New York

  • Nephrology Associates, PC

    Fresh Meadows, New York

  • Nephrology Associates

    Fresh Meadows, New York

  • Triad Internal Medicine

    Asheboro, North Carolina

  • Nephrology Associates, Pllc - Winston-Salem

    Winston-Salem, North Carolina

  • Nephrology Consultants - Oklahoma City

    Oklahoma City, Oklahoma

  • Columbia Nephrology

    Columbia, South Carolina

  • Southeast Renal Research Institute

    Chattanooga, Tennessee

  • Dallas Nephrology Associates (Dna) - Renal Disease Research Institute (Rdri)

    Dallas, Texas

  • Liberty Research Center

    Dallas, Texas

  • R&H Clinical Research

    Katy, Texas

  • E T Nephrology Associates - Lufkin

    Lufkin, Texas

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.